Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China
· Delayed Price · Currency is CNY 46.38
+0.36 (0.78%)
Jun 27, 2025, 2:45 PM CST
SHE:300255 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -184.03 | -249.48 | -1,240 | 17.51 | 233.57 | 252.84 | Upgrade
|
| Depreciation & Amortization | 73.31 | 73.31 | 74.7 | 56.94 | 55.8 | 55.28 | Upgrade
|
| Other Amortization | 1.44 | 1.44 | 0.8 | 0.62 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.78 | 0.78 | 0 | 0.01 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.3 | 1.3 | 1.78 | 2.12 | 0.11 | 0.02 | Upgrade
|
| Loss (Gain) From Sale of Investments | -33.26 | -33.26 | -0.01 | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 6.61 | 6.61 | 15.38 | 6.51 | -0.13 | 2.67 | Upgrade
|
| Other Operating Activities | 93.36 | 169.76 | 730.56 | 98.1 | 62.96 | 57.34 | Upgrade
|
| Change in Accounts Receivable | -21.01 | -21.01 | 284.66 | -97.06 | 91.52 | -90.31 | Upgrade
|
| Change in Inventory | 190 | 190 | 161.28 | -156.01 | -398.02 | -479.01 | Upgrade
|
| Change in Accounts Payable | -82.25 | -82.25 | 13.82 | 72.17 | -48.54 | 23.62 | Upgrade
|
| Operating Cash Flow | 45.27 | 56.22 | 33.73 | 3.13 | 2.87 | -183.58 | Upgrade
|
| Operating Cash Flow Growth | -81.70% | 66.69% | 979.06% | 8.85% | - | - | Upgrade
|
| Capital Expenditures | -220.33 | -239.59 | -239.32 | -431.22 | -308.08 | -199.78 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.06 | 0.06 | 0.02 | 0 | - | - | Upgrade
|
| Investment in Securities | - | - | 0 | - | - | - | Upgrade
|
| Other Investing Activities | 5.56 | 5.77 | 0.45 | -0.1 | 0.78 | -3.07 | Upgrade
|
| Investing Cash Flow | -214.72 | -233.76 | -238.85 | -431.32 | -307.31 | -202.85 | Upgrade
|
| Long-Term Debt Issued | - | 2,000 | 1,346 | 2,816 | 1,581 | 1,579 | Upgrade
|
| Total Debt Issued | 1,713 | 2,000 | 1,346 | 2,816 | 1,581 | 1,579 | Upgrade
|
| Long-Term Debt Repaid | - | -1,687 | -1,529 | -2,030 | -1,182 | -1,099 | Upgrade
|
| Total Debt Repaid | -1,461 | -1,687 | -1,529 | -2,030 | -1,182 | -1,099 | Upgrade
|
| Net Debt Issued (Repaid) | 251.85 | 312.96 | -182.36 | 786.08 | 399.46 | 480.14 | Upgrade
|
| Common Dividends Paid | -120.3 | -119.93 | -107.73 | -124 | -61.89 | -68.46 | Upgrade
|
| Other Financing Activities | -7.18 | -11.3 | -4.85 | -8.63 | 5.39 | -120.01 | Upgrade
|
| Financing Cash Flow | 124.36 | 181.73 | -294.94 | 653.44 | 342.96 | 291.67 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.22 | 0.84 | 3.03 | 12.96 | -3.49 | -1.76 | Upgrade
|
| Net Cash Flow | -42.86 | 5.03 | -497.03 | 238.2 | 35.04 | -96.52 | Upgrade
|
| Free Cash Flow | -175.06 | -183.37 | -205.6 | -428.1 | -305.21 | -383.36 | Upgrade
|
| Free Cash Flow Margin | -17.59% | -17.79% | -14.58% | -18.32% | -10.28% | -16.22% | Upgrade
|
| Free Cash Flow Per Share | -0.19 | -0.20 | -0.22 | -0.49 | -0.33 | -0.41 | Upgrade
|
| Cash Interest Paid | 7.5 | 7.5 | 2.65 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 13.86 | 22.83 | 149.83 | 70.81 | 163.73 | 207.02 | Upgrade
|
| Levered Free Cash Flow | -381.05 | -43.88 | 55.71 | -500.03 | -469.98 | -472.58 | Upgrade
|
| Unlevered Free Cash Flow | -315.26 | 20.39 | 115.97 | -441.88 | -431.04 | -437.7 | Upgrade
|
| Change in Net Working Capital | 95.52 | -296.98 | -995.37 | 135.71 | 381.3 | 523.69 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.